163 related articles for article (PubMed ID: 15700626)
1. Clinical trials referral resource. Current clinical trials of cilengitide, an alpha(v) antagonist in clinical development as an anticancer agent.
Colevas AD; Scharf O; Schoenfeldt M
Oncology (Williston Park); 2004 Dec; 18(14):1778, 1781-2, 1784. PubMed ID: 15700626
[No Abstract] [Full Text] [Related]
2. Cilengitide Merck.
Smith JW
Curr Opin Investig Drugs; 2003 Jun; 4(6):741-5. PubMed ID: 12901235
[TBL] [Abstract][Full Text] [Related]
3. Alpha v integrin inhibitors and cancer therapy.
Tucker GC
Curr Opin Investig Drugs; 2003 Jun; 4(6):722-31. PubMed ID: 12901232
[TBL] [Abstract][Full Text] [Related]
4. Integrin inhibitors reaching the clinic.
Stupp R; Ruegg C
J Clin Oncol; 2007 May; 25(13):1637-8. PubMed ID: 17470853
[No Abstract] [Full Text] [Related]
5. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
[TBL] [Abstract][Full Text] [Related]
6. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.
Reardon DA; Neyns B; Weller M; Tonn JC; Nabors LB; Stupp R
Future Oncol; 2011 Mar; 7(3):339-54. PubMed ID: 21417900
[TBL] [Abstract][Full Text] [Related]
7. Clinical trials referral resource. Clinical trials of MGI-114.
Murgo A; Cannon DJ; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Feb; 13(2):233, 237-8. PubMed ID: 10079472
[No Abstract] [Full Text] [Related]
8. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Reardon DA; Nabors LB; Stupp R; Mikkelsen T
Expert Opin Investig Drugs; 2008 Aug; 17(8):1225-35. PubMed ID: 18616418
[TBL] [Abstract][Full Text] [Related]
9. Anticancer potential of animal venoms and toxins.
Gomes A; Bhattacharjee P; Mishra R; Biswas AK; Dasgupta SC; Giri B
Indian J Exp Biol; 2010 Feb; 48(2):93-103. PubMed ID: 20455317
[TBL] [Abstract][Full Text] [Related]
10. Differential Effects of Integrin
Stojanović N; Dekanić A; Paradžik M; Majhen D; Ferenčak K; Ruščić J; Bardak I; Supina C; Tomicic MT; Christmann M; Osmak M; Ambriović-Ristov A
Mol Pharmacol; 2018 Dec; 94(6):1334-1351. PubMed ID: 30262596
[TBL] [Abstract][Full Text] [Related]
11. Cilengitide: does it really represent a new targeted therapy for recurrent glioblastoma?
Chamberlain MC
J Clin Oncol; 2009 Apr; 27(11):1921; author reply 1922. PubMed ID: 19255301
[No Abstract] [Full Text] [Related]
12. Clinical trials referral resource. Clinical trials of single-agent oxaliplatin.
Ivy SP; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Jul; 13(7):966, 969-70. PubMed ID: 10442343
[No Abstract] [Full Text] [Related]
13. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Tentori L; Dorio AS; Muzi A; Lacal PM; Ruffini F; Navarra P; Graziani G
Oncol Rep; 2008 Apr; 19(4):1039-43. PubMed ID: 18357394
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Reardon DA; Fink KL; Mikkelsen T; Cloughesy TF; O'Neill A; Plotkin S; Glantz M; Ravin P; Raizer JJ; Rich KM; Schiff D; Shapiro WR; Burdette-Radoux S; Dropcho EJ; Wittemer SM; Nippgen J; Picard M; Nabors LB
J Clin Oncol; 2008 Dec; 26(34):5610-7. PubMed ID: 18981465
[TBL] [Abstract][Full Text] [Related]
15. Clinical trials referral resource. Clinical trials using thalidomide.
Phillips PH; Pluda JM; Cheson BD
Oncology (Williston Park); 1996 Oct; 10(10):1498, 1501. PubMed ID: 8905842
[No Abstract] [Full Text] [Related]
16. Clinical trials referral resource. Clinical trials using edatrexate.
Cheson BD; Sorenson JM; Phillips PH
Oncology (Williston Park); 1993 Jul; 7(7):33-4. PubMed ID: 8347459
[No Abstract] [Full Text] [Related]
17. Clinical trials referral resource. Clinical trials of combination regimens containing oxaliplatin.
Ivy SP; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Aug; 13(8):1116-8. PubMed ID: 10499245
[No Abstract] [Full Text] [Related]
18. Clinical trials referral resource. Clinical trials of dolastatin-10.
Wright JJ; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Jan; 13(1):68-70, 75. PubMed ID: 10027199
[No Abstract] [Full Text] [Related]
19. Anti-integrin α
Bouvet M; Claude O; Roux M; Skelly D; Masurkar N; Mougenot N; Nadaud S; Blanc C; Delacroix C; Chardonnet S; Pionneau C; Perret C; Yaniz-Galende E; Rosenthal N; Trégouët DA; Marazzi G; Silvestre JS; Sassoon D; Hulot JS
Sci Rep; 2020 Jul; 10(1):11404. PubMed ID: 32647159
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials referral resource. Clinical trials using bryostatin-1.
Pluda JM; Cheson BD; Phillips PH
Oncology (Williston Park); 1996 May; 10(5):740-2. PubMed ID: 8738829
[No Abstract] [Full Text] [Related]
[Next] [New Search]
